Researchers at Kobe University have unveiled a novel cryopreservation technique that could meaningfully streamline how induced pluripotent stem cells (iPSCs) are stored and handled in laboratory settings. The newly reported method allows iPSCs to be frozen directly within standard culture dishes, eliminating the need for cell transfer prior to cryostorage, an advancement that may significantly improve workflow efficiency across stem cell research, drug discovery, and regenerative medicine. [Read more…]
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL:
A Cost-Optimized Approach
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing services that support robust regulatory pathways without compromising quality or operational discipline. Through our European partnership with Histocell and its EMA-authorized facility in Bilbao, Spain, together with REPROCELL’s U.S. GMP site in Beltsville, Maryland, we offer a dual-site manufacturing network aligned with FDA, EMA, and PMDA expectations.
This infrastructure provides the scale, regulatory alignment, and global flexibility needed for allogeneic therapy programs moving to clinical translation without the excessive costs often linked to iPSC GMP manufacturing. [Read more…]
4 Major Areas of Commercialization for iPS Cells
Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.
In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”
Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery
Financing led by DreamCIS will accelerate and expand development of the company’s industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data analysis to de-risk and accelerate therapeutic development.
SEATTLE — Curi Bio, a leader in delivering human-relevant functional data for drug discovery and development, today announced the close of a $10 million Series B financing round. The round was led by DreamCIS, the leading contract research organization based in Seoul, South Korea, offering comprehensive services for clinical research and regulatory affairs. This strategic partnership is poised to accelerate the translation of Curi Bio’s human-relevant platforms into global clinical success. [Read more…]
Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial
Announcement Highlights:
- Patient enrolment has been completed in Cynata’s Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
- The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
- Primary evaluation period expected to complete in March 2026, with results in June 2026.
- CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 19
- Next Page »